Organ dysfunction in pediatric patients with HSCT-TMA treated with ravulizumab
Sonali Chaudhury(Northwestern University), Franco Locatelli(Università Cattolica del Sacro Cuore), Sarah Lawson(Birmingham Children's Hospital), Michelle Long Schoettler(Children's Healthcare of Atlanta), Christopher C. Dvorak(University of California, San Francisco), Eric Bachman(Merck & Co., Inc., Rahway, NJ, USA (United States)), Aviva C. Krauss(Schneider Children's Medical Center), Peng Liu(Heilongjiang University of Chinese Medicine), Yoshiyuki Takahashi(Nagoya University), Cory Williams(AstraZeneca (Brazil)), David Bueno(Hospital Universitario La Paz)
Cited by 0
Related Papers
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
|Haematologica|2014|389
Angiotensin-converting enzyme and male fertility
|Proceedings of the National Academy of Sciences|1998|336
Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients
|Transplantation and Cellular Therapy|2013|248